When does Jardiance go off patent?
In the US, generics can launch from 2029. Jardiance is sold by Boehringer Ingelheim and Eli Lilly. Lilly's 10-K puts US compound patent expiry at 2029, including pediatric exclusivity; later use patents run to 2034. Sales: Boehringer Ingelheim, EUR 8.8B for the Jardiance family; Lilly separately books $3.4B.
Jardiance's US exclusivity date is based on company guidance. The date comes from the company's own filings or guidance. Secondary patents, new formulations or litigation can still move it. It is a small-molecule drug, so copies are generics. Generic launches usually take most of the US volume within months.
Company guidance. Lilly's 10-K puts US compound patent expiry at 2029, including pediatric exclusivity; later use patents run to 2034. Sales: Boehringer Ingelheim, EUR 8.8B for the Jardiance family; Lilly separately books $3.4B.
Among past small-molecule drugs facing generics: Tecfidera's US sales fell to 21% of their 2019 level in its first full year of generics (2021); Revlimid's US sales fell to 96% of their 2021 level in its first full year of generics (2022) and 57% two years later. Where settlements cap generic volumes, as with Revlimid, the decline is slower. See how past cliffs played out →
Filed with the FDA Generic makers have filed with the FDA. A 2022 approval for Zydus is listed but the product is not marketed, and compound patents with pediatric exclusivity run to February 2029.
| Company (product) | Stage |
|---|---|
| Zydus | FDA-approved 2022; not marketed |
Checked October 2026. Sources: FDA Orange Book: Jardiance patents · Lilly 10-K 2025
Jardiance was selected for the Medicare Drug Price Negotiation Program. Its negotiated Medicare price takes effect in 2026, 66% below its list price. That is 3 years before US generics can launch, so Medicare revenue comes under pressure first. The discount is measured against list price, before the rebates drugmakers already pay, and applies to Medicare only, so the revenue impact is smaller than the headline number.
Jardiance is 32% of Boehringer Ingelheim's 2025 revenue (≈$9.9B of $31.4B). Net sales EUR 27.8B; privately held.
Jardiance is 5.3% of Eli Lilly's 2025 revenue (≈$3.4B of $65.2B). With Trulicity, Taltz, Verzenio, Mounjaro and Zepbound, the drugs tracked here add up to 82% of Eli Lilly's revenue losing US exclusivity by 2036.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Jardiance is highlighted.